http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110639002-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110639002-B |
| titleOfInvention | Application of carfilzomib in preparation of drug for treating osteosarcoma |
| abstract | The invention provides a new function of a proteasome inhibitor carfilzomib, which is used for preparing a medicine for treating osteosarcoma: can induce osteogenic differentiation of osteosarcoma, and can be used for treating osteosarcoma. Experiments prove that the carfilzomib with medium and high doses can induce apoptosis of osteosarcoma cells, and the carfilzomib with low concentration can effectively induce osteogenic differentiation of the osteosarcoma cells, and the specific expression is as follows: causing the calcified nodules to increase in osteosarcoma cells F5M2 and U-2 OS; an increase in alkaline phosphatase activity; increased expression of osteogenic differentiation markers (ALP, OPN, Runx 2). |
| priorityDate | 2019-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 51.